CB1receptor antagonists: new discoveries leading to new perspectives
The DOI matches its Crossref record.
Abstract
CB1 receptor antagonists were among the most promising drug targets in the last decade. They have been explored and found to be effective as therapeutic agents for obesity and related cardiometabolic problems; however, use of rimonabant, the first marketed CB1 receptor antagonist, has been suspended because of its anxiogenic and depressogenic side effects. Because some other antiobesity drugs, like dexfenfluramine or sibutramine, were also suspended, the unmet need for drugs that reduce body weight became enormous. One approach that emerged was the use of CB1 receptor antagonists that poorly cross the blood brain barrier, the second, the development of neutral antagonists instead of inverse agonists, and the third, use of personalized medicine, namely the selection of the patient population without psychiatric side effects. In this review, we dissect the peripheral and central mechanisms involved in the effects of CB1 receptor antagonists and argue that central mechanisms are more or less involved in most cardiometabolic therapeutic effects and thus, among patients with unsatisfactory therapeutic response to compounds with peripheral action, centrally acting antagonists may be needed. An analysis of pharmacogenetic factors may help to identify persons who are at no or low risk for psychiatric adverse effects. Here, we present the models and identify molecular mechanisms and receptors involved in the effects of stress‐, anxiety‐ and depression‐related neurocircuitries sensitive to CB1 receptor antagonists, like the serotonergic, noradrenergic and dopaminergic systems, which are not only regulated by CB1 receptors, but also regulate the synthesis of the endocannabinoid 2‐arachidonoyl‐glycerol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Kullmann, D. M., Moreau, A. W., Bakiri, Y., & Nicholson, E. (2012) · Neuron · doi:10.1016/j.neuron.2012.07.030 · Cited by 234
Enhancement of meditation analgesia by opioid antagonist in experienced meditators
May, L. M., Kosek, P., Zeidan, F., & Berkman, E. T. (2018) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000580 · Cited by 24
Metadata
- Authors
- Kirilly, E., Gonda, X., & Bagdy, G.
- Venue
- Acta Physiologica
- Publisher
- Wiley
- Published
- 2012-02-11
- Volume
- 205
- Issue
- 1
- Pages
- 41-60
- ISSN
- 1748-1708 (ISSN-L)
- 1748-1716
- OpenAlex
- W4242768688
- Cited by
- 60
- References
- 0
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CB1receptor antagonists: new discoveries leading to new perspectives. https://app.cochat.ai/papers/10.1111/j.1748-1716.2011.02402.x
- The paper
- Kirilly, E., Gonda, X., & Bagdy, G. (2012). CB1receptor antagonists: new discoveries leading to new perspectives. Acta Physiologica. https://doi.org/10.1111/j.1748-1716.2011.02402.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.